154 related articles for article (PubMed ID: 22669112)
1. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
Nicolatou-Galitis O; Migkou M; Psyrri A; Bamias A; Pectasides D; Economopoulos T; Raber-Durlacher JE; Dimitriadis G; Dimopoulos MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Feb; 113(2):234-8. PubMed ID: 22669112
[TBL] [Abstract][Full Text] [Related]
2. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Brunello A; Saia G; Bedogni A; Scaglione D; Basso U
Bone; 2009 Jan; 44(1):173-5. PubMed ID: 18849018
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib related osteonecrosis of jaw: a case report.
Fleissig Y; Regev E; Lehman H
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Mar; 113(3):e1-3. PubMed ID: 22676833
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Hoefert S; Eufinger H
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw related to sunitinib.
Koch FP; Walter C; Hansen T; Jäger E; Wagner W
Oral Maxillofac Surg; 2011 Mar; 15(1):63-6. PubMed ID: 20401503
[TBL] [Abstract][Full Text] [Related]
7. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
[TBL] [Abstract][Full Text] [Related]
9. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
10. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A
Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
[TBL] [Abstract][Full Text] [Related]
13. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
[TBL] [Abstract][Full Text] [Related]
15. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
Park S; Lee J; Park SH; Park JO; Kang WK; Park YS; Cho JH; Lim HY
Chemotherapy; 2010; 56(6):485-91. PubMed ID: 21099221
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
20. Severe neurological symptoms in a patient with advanced renal cell carcinoma treated with sunitinib.
Duchnowska R; Miciuk B; Bodnar L; Waśniewski L; Szczylik C
J Oncol Pharm Pract; 2013 Jun; 19(2):186-9. PubMed ID: 23037634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]